Khatibi E Ali, Samsioe Göran, Li Cairu, Lidfeldbt Jonas, Agardh Carl-David, Nerbrand Christina
Department of Obstetrics and Gynaecology, Lund University Hospital, Lund S-221 85, Sweden.
Maturitas. 2004 Aug 20;48(4):438-45. doi: 10.1016/j.maturitas.2003.10.001.
To delineate the use of various drugs particularly pertaining to allergy and upper gastrointestinal problems in relation to hormone status in middle aged women.
An analysis from a population-based study on women born between 1935 and 1945 and lived in the Lund area southern Sweden. Of 10,766 women, 6,917 provided complete data sets; in turn 5,673 were assessed for the use of medication in this study. Among the cohort, 9% of women were premenopausal (PM), 54% were postmenopausal without hormone replacement therapy (PM0) and 37% were current hormone replacement therapy users (PMT).
There were 7 (1.3%) women in PM, 11 (0.4%) in PM0 and 21 (1.0%) in PMT group who used loratadine regularly. There was a significant difference between the PM and PM0 groups and also between the PM0 and PMT groups in the use of loratadine (P < 0.05 ). Among 21 loratadine users in PMT group 4 (19%) used transdermal patches and 17 (81%) used oral HRT. The result for omeprazole use was as follows: 4 (0.8%) of PM group, 39 (1.3%) of PM0 group and 42 (2.0%) of PMT group. The use of omeprazole was significantly higher in the PMT group than in the PM (P = 0.05 ) and PM0 group (P < 0.05 ). There was no relation between the use of omeprazole and smoking or alcohol consumption.
Use of hormone replacement therapy seems to be related to a higher frequency of omeprazole and loratadine use, which implies that hormone replacement therapy, may be associated with more upper gastrointestinal symptoms as well as allergy.
描述中年女性在激素状态方面,各类药物尤其是与过敏和上消化道问题相关药物的使用情况。
对一项基于人群的研究进行分析,该研究对象为1935年至1945年间出生且居住在瑞典南部隆德地区的女性。在10766名女性中,6917人提供了完整数据集;进而在本研究中对5673人使用药物的情况进行评估。在该队列中,9%的女性处于绝经前(PM),54%的女性处于未接受激素替代疗法的绝经后(PM0),37%的女性为当前激素替代疗法使用者(PMT)。
PM组有7名(1.3%)女性、PM0组有11名(0.4%)女性、PMT组有21名(1.0%)女性经常使用氯雷他定。氯雷他定的使用在PM组和PM0组之间以及PM0组和PMT组之间存在显著差异(P<0.05)。在PMT组的21名氯雷他定使用者中,4名(19%)使用透皮贴剂,17名(81%)使用口服激素替代疗法。奥美拉唑的使用结果如下:PM组4名(0.8%)、PM0组39名(1.3%)、PMT组42名(2.0%)。PMT组奥美拉唑的使用显著高于PM组(P = 0.05)和PM0组(P<0.05)。奥美拉唑的使用与吸烟或饮酒无关。
激素替代疗法的使用似乎与奥美拉唑和氯雷他定的较高使用频率相关,这意味着激素替代疗法可能与更多的上消化道症状以及过敏有关。